Search

Your search keyword '"Sculpher, Mark"' showing total 1,215 results
Start Over Author "Sculpher, Mark"
1,215 results on '"Sculpher, Mark"'

2. System-wide approaches to antimicrobial therapy and antimicrobial resistance in the UK: the AMR-X framework

Author

Abel, Kathryn, Agnew, Emily, Amos, James, Armstrong, Natalie, Armstrong-James, Darius, Ashfield, Thomas, Aston, Stephen, Baillie, J Kenneth, Baldwin, Steven, Barlow, Gavin, Bartle, Victoria, Bielicki, Julia, Brown, Colin, Carrol, Enitan, Clements, Michelle, Cooke, Graham, Dane, Aaron, Dark, Paul, Day, Jeremy, de-Soyza, Anthony, Dowsey, Andrew, Evans, Stephanie, Eyre, David, Felton, Timothy, Fowler, Tom, Foy, Robbie, Gannon, Karen, Gerada, Alessandro, Goodman, Anna, Harman, Tracy, Hayward, Gail, Holmes, Alison, Hopkins, Susan, Howard, Philip, Howard, Alexander, Hsia, Yingfen, Knight, Gwen, Lemoine, Nick, Koh, James, Macgowan, Alasdair, Marwick, Charis, Moore, Catrin, O’Brien, Seamus, Oppong, Raymond, Peacock, Sharon, Pett, Sarah, Pouwels, Koen, Queree, Chris, Rahman, Najib, Sculpher, Mark, Shallcross, Laura, Sharland, Michael, Singh, Jasvinder, Stoddart, Karen, Thomas-Jones, Emma, Townsend, Andrew, Ustianowski, Andrew, Van Staa, Tjeerd, Walker, Sarah, White, Peter, Wilson, Paul, Buchan, Iain, Woods, Beth, Bower, Peter, Llewelyn, Martin, and Hope, William

Published
2024
Full Text
View/download PDF

3. A qualitative study on the feasibility and acceptability of institutionalizing health technology assessment in Malawi

Author

Mfutso-Bengo, Joseph, Jeremiah, Faless, Kasende-Chinguwo, Florence, Ng’ambi, Wingston, Nkungula, Nthanda, Kazanga-Chiumia, Isabel, Juma, Mercy, Chawani, Marlen, Chinkhumba, Jobiba, Twea, Pakwanja, Chirwa, Emily, Langwe, Kate, Manthalu, Gerald, Ngwira, Lucky Gift, Nkhoma, Dominic, Colbourn, Tim, Revill, Paul, and Sculpher, Mark

Published
2023
Full Text
View/download PDF

5. The Lancet Commission on prostate cancer: planning for the surge in cases

Author

James, Nicholas D, Tannock, Ian, N'Dow, James, Feng, Felix, Gillessen, Silke, Ali, Syed Adnan, Trujillo, Blanca, Al-Lazikani, Bissan, Attard, Gerhardt, Bray, Freddie, Compérat, Eva, Eeles, Ros, Fatiregun, Omolara, Grist, Emily, Halabi, Susan, Haran, Áine, Herchenhorn, Daniel, Hofman, Michael S, Jalloh, Mohamed, Loeb, Stacy, MacNair, Archie, Mahal, Brandon, Mendes, Larissa, Moghul, Masood, Moore, Caroline, Morgans, Alicia, Morris, Michael, Murphy, Declan, Murthy, Vedang, Nguyen, Paul L, Padhani, Anwar, Parker, Charles, Rush, Hannah, Sculpher, Mark, Soule, Howard, Sydes, Matthew R, Tilki, Derya, Tunariu, Nina, Villanti, Paul, and Xie, Li-Ping

Published
2024
Full Text
View/download PDF

14. Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa

Author

Phillips, Andrew N, Cambiano, Valentina, Revill, Paul, Nakagawa, Fumiyo, Lundgren, Jens D, Bansi-Matharu, Loveleen, Mabugu, Travor, Sculpher, Mark, Garnett, Geoff, Staprans, Silvija, Becker, Stephen, Murungu, Joseph, Lewin, Sharon R, Deeks, Steven G, and Hallett, Timothy B

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Immunology, Medical Microbiology, Infectious Diseases, Clinical Research, HIV/AIDS, Comparative Effectiveness Research, Clinical Trials and Supportive Activities, Cost Effectiveness Research, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Anti-HIV Agents, Cost-Benefit Analysis, Female, Forecasting, HIV Infections, Humans, Incidence, Male, Middle Aged, Models, Theoretical, Poverty, Young Adult, Zimbabwe, HIV, cure, economic evaluation, model, antiretroviral therapy, Biological Sciences, Medical and Health Sciences, Microbiology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundIt is unknown what properties would be required to make an intervention in low income countries that can eradicate or control human immunodeficiency virus (HIV) without antiretroviral therapy (ART) cost-effective.MethodsWe used a model of HIV and ART to investigate the effect of introducing an ART-free viral suppression intervention in 2022 using Zimbabwe as an example country. We assumed that the intervention (cost: $500) would be accessible for 90% of the population, be given to those receiving effective ART, have sufficient efficacy to allow ART interruption in 95%, with a rate of viral rebound of 5% per year in the first 3 months, and a 50% decline in rate with each successive year.ResultsAn ART-free viral suppression intervention with these properties would result in >0.53 million disability-adjusted-life-years averted over 2022-2042, with a reduction in HIV program costs of $300 million (8.7% saving). An intervention of this efficacy costing anything up to $1400 is likely to be cost-effective in this setting.ConclusionsInterventions aimed at curing HIV infection have the potential to improve overall disease burden and to reduce costs. Given the effectiveness and cost of ART, such interventions would have to be inexpensive and highly effective.

Published
2016

15. Percutaneous Revascularisation for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial

Author

Chivardi, Carlos, primary, Morgan, Holly, additional, Sculpher, Mark J., additional, Clayton, Tim, additional, Evans, Richard, additional, Dodd, Matthew, additional, Petrie, Mark, additional, Rinaldi, Christopher A., additional, O'Kane, Peter, additional, Brown, Louise, additional, Perera, Divaka, additional, and Saramago, Pedro, additional

Published
2023
Full Text
View/download PDF

16. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness

Author

Woods, Beth S., Sideris, Eleftherios, Sydes, Matthew R., Gannon, Melissa R., Parmar, Mahesh K.B., Alzouebi, Mymoona, Attard, Gerhardt, Birtle, Alison J., Brock, Susannah, Cathomas, Richard, Chakraborti, Prabir R., Cook, Audrey, Cross, William R., Dearnaley, David P., Gale, Joanna, Gibbs, Stephanie, Graham, John D., Hughes, Robert, Jones, Rob J., Laing, Robert, Mason, Malcolm D., Matheson, David, McLaren, Duncan B., Millman, Robin, O'Sullivan, Joe M., Parikh, Omi, Parker, Christopher C., Peedell, Clive, Protheroe, Andrew, Ritchie, Alastair W.S., Robinson, Angus, Russell, J. Martin, Simms, Matthew S., Srihari, Narayanan N., Srinivasan, Rajaguru, Staffurth, John N., Sundar, Santhanam, Thalmann, George N., Tolan, Shaun, Tran, Anna T.H., Tsang, David, Wagstaff, John, James, Nicholas D., and Sculpher, Mark J.

Published
2018
Full Text
View/download PDF

17. We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessment

Author

Charlton, Victoria, primary, DiStefano, Michael, additional, Mitchell, Polly, additional, Morrell, Liz, additional, Rand, Leah, additional, Badano, Gabriele, additional, Baker, Rachel, additional, Calnan, Michael, additional, Chalkidou, Kalipso, additional, Culyer, Anthony, additional, Howdon, Daniel, additional, Hughes, Dyfrig, additional, Lomas, James, additional, Max, Catherine, additional, McCabe, Christopher, additional, O'Mahony, James F., additional, Paulden, Mike, additional, Pemberton-Whiteley, Zack, additional, Rid, Annette, additional, Scuffham, Paul, additional, Sculpher, Mark, additional, Shah, Koonal, additional, Weale, Albert, additional, and Wester, Gry, additional

Published
2023
Full Text
View/download PDF

18. Global Health Economics

Author

Revill, Paul, primary, Suhrcke, Marc, additional, Moreno-Serra, Rodrigo, additional, Sculpher, Mark, additional, and Goddard, Maria, additional

Published
2020
Full Text
View/download PDF

27. Randomised trial of stable chest pain investigation: 3-year clinical and quality of life results from CE-MARC 2

Author

Everett, Colin C., primary, Berry, Colin, additional, McCann, Gerry P., additional, Fernandez, Catherine, additional, Reynolds, Catherine, additional, Bucciarelli-Ducci, Chiara, additional, Dall’Armellina, Erica, additional, Prasad, Abhiram, additional, Foley, James R., additional, Mangion, Kenneth, additional, Bijsterveld, Petra, additional, Brown, Julia, additional, Stocken, Deborah, additional, Walker, Simon, additional, Sculpher, Mark, additional, Plein, Sven, additional, and Greenwood, John P., additional

Published
2023
Full Text
View/download PDF

28. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial

Author

Al Sarakbi, Wail, Barber, Sarah, Barnett, Gillian, Bliss, Peter, Dewar, John, Eaton, David, Ebbs, Stephen, Ellis, Ian, Evans, Philip, Harris, Emma, James, Hayley, Kirwan, Cliona, Kirk, Julie, Mayles, Helen, McIntyre, Anne, Mills, Judith, Poynter, Andrew, Provenzano, Elena, Rawlings, Christine, Sculpher, Mark, Sumo, Georges, Sydenham, Mark, Tutt, Andrew, Twyman, Nicola, Venables, Karen, Winship, Anna, Winstanley, John, Wishart, Gordon, Thompson, Alastair, Coles, Charlotte E, Griffin, Clare L, Kirby, Anna M, Titley, Jenny, Agrawal, Rajiv K, Alhasso, Abdulla, Bhattacharya, Indrani S, Brunt, Adrian M, Ciurlionis, Laura, Chan, Charlie, Donovan, Ellen M, Emson, Marie A, Harnett, Adrian N, Haviland, Joanne S, Hopwood, Penelope, Jefford, Monica L, Kaggwa, Ronald, Sawyer, Elinor J, Syndikus, Isabel, Tsang, Yat M, Wheatley, Duncan A, Wilcox, Maggie, Yarnold, John R, and Bliss, Judith M

Published
2017
Full Text
View/download PDF

30. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction: Cost-Effectiveness Analysis of the REVIVED-BCIS2 Trial.

Author

Chivardi, Carlos, Morgan, Holly, Sculpher, Mark J., Clayton, Tim, Evans, Richard, Dodd, Matthew, Petrie, Mark, Rinaldi, Christopher A., O'Kane, Peter, Brown, Louise, Perera, Divaka, and Saramago, Pedro

Abstract

BACKGROUND: Percutaneous coronary intervention (PCI) is frequently undertaken in patients with ischemic left ventricular systolic dysfunction. The REVIVED (Revascularization for Ischemic Ventricular Dysfunction)-BCIS2 (British Cardiovascular Society-2) trial concluded that PCI did not reduce the incidence of all-cause death or heart failure hospitalization; however, patients assigned to PCI reported better initial health-related quality of life than those assigned to optimal medical therapy (OMT) alone. The aim of this study was to assess the cost-effectiveness of PCI+OMT compared with OMT alone. METHODS: REVIVED-BCIS2 was a prospective, multicenter UK trial, which randomized patients with severe ischemic left ventricular systolic dysfunction to either PCI+OMT or OMT alone. Health care resource use (including planned and unplanned revascularizations, medication, device implantation, and heart failure hospitalizations) and health outcomes data (EuroQol 5-dimension 5-level questionnaire) on each patient were collected at baseline and up to 8 years post-randomization. Resource use was costed using publicly available national unit costs. Within the trial, mean total costs and quality-adjusted life-years (QALYs) were estimated from the perspective of the UK health system. Cost-effectiveness was evaluated using estimated mean costs and QALYs in both groups. Regression analysis was used to adjust for clinically relevant predictors. RESULTS: Between 2013 and 2020, 700 patients were recruited (mean age: PCI+OMT=70 years, OMT=68 years; male (%): PCI+OMT=87, OMT=88); median follow-up was 3.4 years. Over all follow-ups, patients undergoing PCI yielded similar health benefits at higher costs compared with OMT alone (PCI+OMT: 4.14 QALYs, £22 352; OMT alone: 4.16 QALYs, £15 569; difference: -0.015, £6782). For both groups, most health resource consumption occurred in the first 2 years post-randomization. Probabilistic results showed that the probability of PCI being cost-effective was 0. CONCLUSIONS: A minimal difference in total QALYs was identified between arms, and PCI+OMT was not cost-effective compared with OMT, given its additional cost. A strategy of routine PCI to treat ischemic left ventricular systolic dysfunction does not seem to be a justifiable use of health care resources in the United Kingdom. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01920048. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma in the TRISST trial.

Author

Huo, Dacheng, primary, Huddart, Robert A, additional, Cafferty, Fay Helen, additional, Murphy, Laura, additional, Rustin, Gordon J. S., additional, Sohaib, Syed A, additional, Schiavone, Francesca, additional, Kaplan, Richard S., additional, Joffe, Johnathan K, additional, Sculpher, Mark, additional, and Pedro, Saramago, additional

Published
2023
Full Text
View/download PDF

35. Using Age-Specific Values for Pediatric HRQoL in a Cost-Effectiveness Analysis:Is There a Problem to Be Solved? If So, How?

Author

Devlin, Nancy J., Pan, Tianxin, Sculpher, Mark, Jit, Mark, Stolk, Elly, Rowen, Donna, van Hout, Barend, Norman, Richard, Devlin, Nancy J., Pan, Tianxin, Sculpher, Mark, Jit, Mark, Stolk, Elly, Rowen, Donna, van Hout, Barend, and Norman, Richard

Abstract

Value sets for the EQ-5D-Y-3L published to date appear to have distinctive characteristics compared with value sets for corresponding adult instruments: in many cases, the value for the worst health state is higher and there are fewer values < 0. The aim of this paper is to consider how and why values for child and adult health differ; and what the implications of that are for the use of EQ-5D-Y-3L values in economic evaluations to inform healthcare resource allocation decisions. We posit four potential explanations for the differences in values: (a) The wording of severity labels may mean the worst problems on the EQ-5D-Y-3L are descriptively less severe than those on the EQ-5D-5L; (b) Adults may genuinely consider that children are less badly affected than adults by descriptively similar health issues. That is, for any given health problem, adult respondents in valuation studies consider children’s overall health-related quality of life (HRQoL) on average to be higher than that for adults; (c) Values are being sought by eliciting adults’ stated preferences for HRQoL in another person, rather than in themselves (regardless of whether the ‘other person’ concerned is a child); and (d) The need to elicit preferences for child HRQoL that are anchored at dead = 0 invokes special considerations regarding children’s survival. Existing evidence does not rule out the possibility that (c) and (d) exert an upward bias in values. We consider the implications of that for the interpretation and use of values for pediatric HRQoL. Alternative methods for valuing children’s HRQoL in a manner that is not ‘age specific’ are possible and may help to avoid issues of non-comparability. Use of these methods would place the onus on health technology assessment bodies to reflect any special considerations regarding child quality-adjusted life-year gains.

Published
2023

38. Economic evaluation of minimal access surgery : the case of surgical treatment for menorrhagia

Author

Sculpher, Mark John, Buxton, M. J., and Drummond, M.

Subjects
362.1, Hysterectomy, Transcervical endometrial resection
Abstract

The purpose of this thesis is to explore the methodological and empirical issues relating to the economic evaluation of minimal access surgery (MAS). Given the likely increase in the utilisation of economic analysis in this area, it is crucial to explore whether the methods of economic evaluation have limitations in the face of the particular characteristics of MAS. The comparison of abdominal hysterectomy (AH) and transcervical endometrial resection (TCRE), for the treatment of menorrhagia, is used as a vehicle to develop methods in relation to MAS. Having reviewed the literature and issues relating to the economic analysis of this group of technologies, the empirical starting point of the thesis is the assessment of the limitations of economic evaluations alongside clinical trials, using a trial comparing AH and TCRE. Three major areas of weakness are identified, and alternative ways of addressing these weaknesses are explored in the remainder of the thesis. The first area of methodological development relates to the measure of benefit used in economic evaluation of MAS. In this clinical context, it is argued that the trade-offs that exist between MAS and conventional surgery, in terms of process characteristics and outcomes, should result in an important role for patients' preferences in the construction of a benefit measure. A cost-utility analysis using the standard quality-adjusted life year (GALY) is undertaken, using trial data augmented with valuation data from a further study. The lack of consistency between individual preferences and standard QALYs suggests a major weakness with this measure of benefit. The strengths and weaknesses of an alternative measure of benefit in cost-utility analysis - the ex ante healthy years equivalent (HYE) - are assessed based on a further valuation study. It is shown that it is feasible to elicit ex ante HYEs from patients and that this measure of benefit exhibits some consistency with other expressions of patients' preferences. However, the HYE is likely to impose a greater measurement burden than the standard QALY. The second area of methodological development in the thesis is the analysis of the generalisability of trial-based economic evaluation, given the limitations that often exist with the external validity of trials. A framework is developed within which trial and observational data can be synthesised. This facilitates the use of sensitivity analysis to explore the robustness of base-case (trial-generated) results to alternative sources of data, which may be more representative of routine practice. The third area of methodological development stems from the importance of patients' preferences in relation to MAS. This element relates to the use of methods to model and to evaluate management strategies which use patients' preferences to determine treatment allocation. It is concluded that preference-based decision making has the potential to be cost effective in relation to TCRE and AH, and MAS applications more generally. The thesis demonstrates the importance of continued development in the detailed methods of economic evaluation.

Published
1996

40. Developing a Modeling Framework for Quantifying the Health and Cost Implications of Antibiotic Resistance for Surgical Procedures

Author

Davies, Heather, primary, Russell, Joel, additional, Varghese, Angel, additional, Holmes, Hayden, additional, Soares, Marta O., additional, Woods, Beth, additional, Puig-Peiro, Ruth, additional, Evans, Stephanie, additional, Tierney, Rory, additional, Mealing, Stuart, additional, Sculpher, Mark, additional, and Robotham, Julie V., additional

Published
2023
Full Text
View/download PDF

41. Additional file 1 of A qualitative study on the feasibility and acceptability of institutionalizing health technology assessment in Malawi

Author

Mfutso-Bengo, Joseph, Jeremiah, Faless, Kasende-Chinguwo, Florence, Ng’ambi, Wingston, Nkungula, Nthanda, Kazanga-Chiumia, Isabel, Juma, Mercy, Chawani, Marlen, Chinkhumba, Jobiba, Twea, Pakwanja, Chirwa, Emily, Langwe, Kate, Manthalu, Gerald, Ngwira, Lucky Gift, Nkhoma, Dominic, Colbourn, Tim, Revill, Paul, and Sculpher, Mark

Abstract

Key Informant Interview Guide

Published
2023
Full Text
View/download PDF

42. sj-docx-1-mpp-10.1177_23814683231152885 – Supplemental material for Developing a Modeling Framework for Quantifying the Health and Cost Implications of Antibiotic Resistance for Surgical Procedures

Author

Davies, Heather, Russell, Joel, Varghese, Angel, Holmes, Hayden, Soares, Marta O., Woods, B., Puig-Peiro, Ruth, Evans, Stephanie, Tierney, Rory, Mealing, Stuart, Sculpher, Mark, and Robotham, Julie V.

Subjects
111799 Public Health and Health Services not elsewhere classified, FOS: Health sciences
Abstract

Supplemental material, sj-docx-1-mpp-10.1177_23814683231152885 for Developing a Modeling Framework for Quantifying the Health and Cost Implications of Antibiotic Resistance for Surgical Procedures by Heather Davies, Joel Russell, Angel Varghese, Hayden Holmes, Marta O. Soares, B. Woods, Ruth Puig-Peiro, Stephanie Evans, Rory Tierney, Stuart Mealing, Mark Sculpher and Julie V. Robotham in MDM Policy & Practice

Published
2023
Full Text
View/download PDF

43. Additional file 2 of A qualitative study on the feasibility and acceptability of institutionalizing health technology assessment in Malawi

Author

Mfutso-Bengo, Joseph, Jeremiah, Faless, Kasende-Chinguwo, Florence, Ng’ambi, Wingston, Nkungula, Nthanda, Kazanga-Chiumia, Isabel, Juma, Mercy, Chawani, Marlen, Chinkhumba, Jobiba, Twea, Pakwanja, Chirwa, Emily, Langwe, Kate, Manthalu, Gerald, Ngwira, Lucky Gift, Nkhoma, Dominic, Colbourn, Tim, Revill, Paul, and Sculpher, Mark

Abstract

Focus Group Discussion Guide

Published
2023
Full Text
View/download PDF

46. Evaluation of ‘Replicability’ model project for early detection and treatment of leprosy and estimating the prevalence and severity of disability in the community in Champa district, Chhattisgarh, India

Author

Choudhury, Sopna, Darlong, Joydeepa, Govindasamy, Karthikeyan, Ilozumba, Onaedo, Gill, Paramjit, Griffiths, Frances, Watson, Sam, sculpher, mark, de Faria, Rita, Sartori, Jo, and Lilford, Richard

Subjects
M. leprae, Medical Sciences, evaluation, Neglected Tropical Disease, Mental and Social Health, NTDs, Diseases, Social and Behavioral Sciences, Stigma, Medical Education, self-care, Medicine and Health Sciences, Self-management, Public Health, Community health, Ulcer
Abstract

This protocol describes an evaluation of the Replicability Model (RM) project and estimation of the prevalence of disabilities due to leprosy in the district of Janjgir-Champa, state of Chhattisgarh, India. This is funded by National Institute for Health Research (NIHR: 200132) using UK aid from the UK Government to support global health research.

Published
2022
Full Text
View/download PDF

48. Recommendations on Perspectives for the Reference Case

Author

Neumann, Peter J., primary, Sanders, Gillian D., additional, Basu, Anirban, additional, Brock, Dan W., additional, Feeny, David, additional, Krahn, Murray, additional, Kuntz, Karen M., additional, Meltzer, David O., additional, Owens, Douglas K., additional, Prosser, Lisa A., additional, Salomon, Joshua A., additional, Sculpher, Mark J., additional, Trikalinos, Thomas A., additional, Russell, Louise B., additional, Siegel, Joanna E., additional, and Ganiats, Theodore G., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results